MK&A has been acquired by Cláudia Hirawat, industry leader and patient advocate, enhancing the firm’s expertise and network. Mark Krueger has been appointed chief strategic officer; Ellen Coleman has been appointed president and chief executive officer.
Jane Reese-Coulbourne changed the world of cancer by insisting that patients mattered. While cancer has taken her from us at too young an age, her impact will live on.
We have a proven track record in achieving tangible results that enhance our clients’ reputations and ensure their products’ success in the marketplace.
MK&A is a leading consultant to pharmaceutical, biotech, device and diagnostic companies around the world in their quests to deliver quality care through innovative and effective partnerships with patient, consumer and professional groups.
MK&A has unmatched breadth and depth of experience in a broad range of therapeutic areas including but not limited to cardiovascular disease, diabetes, hematology, infectious diseases, mental health, neurology, oncology, and rare diseases.
MK&A has long, trusted relationships with global, regional, and national patient, consumer, and professional groups, as well as a deep understanding of intergroup dynamics, perceptions of industry, and examples of effective partnerships.
MK&A associates have decades of experience, having served in leadership positions in advocacy, clinical research, industry, market research, policy, and more. This wealth of experience enables the firm to offer a strategic and innovative approach to advance mutual goals between clients and key stakeholders.
We can help your company build mutually beneficial partnerships with patient, consumer, and professional groups and other key influencers to help you reach the objectives you share with key constituents. Our services are customized to your company and your business. We quickly determine your needs and offer realistic solutions tailored specifically to the unique issues and budgets involved.